About Uniphar Biotech
Uniphar Biotech is a company based in Chandigarh (India) founded in 2010. It operates as a B2B. Uniphar Biotech offers products and services including ACEBR’OPUT-100, ALGEN, AMBRODEX-A, ANSAC-P, and AZILE-500. Uniphar Biotech operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others.
- Headquarter Chandigarh, India
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Uniphar Biotech Private Limited
- Date of Incorporation 13 Sep, 2013
- Jurisdiction Chandigarh, Chandigarh, India
-
Annual Revenue
$694.51 K (USD)26.97as on Mar 31, 2022
-
Net Profit
$18.45 K (USD)122.85as on Mar 31, 2022
-
EBITDA
$46.76 K (USD)-4.54as on Mar 31, 2022
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Uniphar Biotech
Uniphar Biotech offers a comprehensive portfolio of products and services, including ACEBR’OPUT-100, ALGEN, AMBRODEX-A, ANSAC-P, and AZILE-500.
Tablet for respiratory relief with Acebrophylline
Syrup for urinary alkalinization and pH balance
Cough syrup with Ambroxol for respiratory support
Pain relief tablet with Aceclofenac and Paracetamol
Antibiotic tablet for bacterial infections
Funding Insights of Uniphar Biotech
Detailed funding history for Uniphar Biotech
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Uniphar Biotech
Investment portfolio details for Uniphar Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Uniphar Biotech
Detailed financials for Uniphar Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Uniphar Biotech Comparisons
Peer comparison for Uniphar Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Uniphar Biotech
Uniphar Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| Locked | Locked | Locked |
Industrial and therapeutic proteins are manufactured by Aperiam Bio.
|
|
| Locked | Locked | Locked |
Proprietary, GMP-grade, and non-GMP peptides are manufactured by PolyPeptide Labs.
|
Detailed competitors of Uniphar Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Uniphar Biotech
Complete news archive for Uniphar Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Uniphar Biotech
Uniphar Biotech was founded in 2010.
Uniphar Biotech is headquartered in Chandigarh, India.
Annual revenue of Uniphar Biotech is $694.51K as on Mar 31, 2022.
Uniphar Biotech Private Limited is an ISO-certified pharmaceutical company based in India. It produces and markets a wide range of products including tablets, capsules, syrups, injectables, and Ayurvedic items. The company engages in contract manufacturing and third-party orders, while offering PCD Pharma Franchise opportunities to distributors. It emphasizes quality assurance through GMP standards and serves the healthcare industry via ethical practices and nationwide distribution networks in Chandigarh.
Uniphar Biotech's top competitors include Enzene Biosciences, Hybio Pharmaceutical and PolyPeptide.
Uniphar Biotech offers ACEBR’OPUT-100, ALGEN, AMBRODEX-A, ANSAC-P, and AZILE-500.